文章预览
Suzhou, June 17, 2024-Kintor
Pharmaceutical Limited (“Kintor Pharma”, HKEX: 9939), announced that the Company has completed the first subject enrollment
in the phase II clinical trial in China of its in-house developed androgen receptor proteolysis
targeting chimera (“PROTAC”)
compound GT20029 for the treatment of acne. Developed by the Company’s in-house
PROTAC platform, GT20029 is the first topical PROTAC compound which has entered
the phase II clinical stage worldwide. The Phase II Clinical Trial is a
multi-center, randomized, double-blind, placebo-controlled study,
which is designed to evaluate the efficacy, safety and pharmacokinetics of
GT20029 for the treatment of acne through the adoption of GT20029 0.5% once-a-day (“QD”) and 1% QD as the drug-related dosage. The Phase II Clinical Trial involves a total of 10 clinical
research centers in China, and Professor Xiang Leihong(项蕾红)
from Fudan University Huashan Hospital (复旦大学附属华山医院) is
………………………………
